Gland Pharma Limited has announced its unaudited consolidated financial results for the quarter ended September 30, 2024, showing modest revenue growth but a decline in profitability.
For Q2 FY2025, Gland Pharma reported revenue from operations of ₹1,405.83 crore, reflecting a 2.4% increase from ₹1,373.42 crore in the same period last year. This slight growth indicates the company’s steady revenue performance despite market challenges.
However, net profit for the quarter dropped significantly, falling by 15.7% to ₹163.53 crore from ₹194.08 crore in Q2 FY2024. The decline in net profit highlights cost pressures or other factors impacting the company’s bottom line.
For the half-year period ending September 30, 2024, the company’s revenue stood at ₹2,807.54 crore, up from ₹2,582.12 crore in the corresponding period last year. The half-year net profit amounted to ₹307.29 crore, down from ₹388.18 crore in H1 FY2024, showcasing a challenging period for profitability.
Gland Pharma continues to navigate through a competitive environment, balancing revenue generation with cost management to optimize its financial results.
